COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Xlife Sciences AG Publishes 2024 ESG Report: Sustainable Value Creation as a Strategic Core
Xlife Sciences AG publishes 2024 ESG Report showcasing sustainable value creation through integrating ESG principles into corporate strategy and portfolio management in life sciences sector -
-
-
COMMUNIQUÉ DE PRESSE
Xlife Sciences AG Half-Year Report 2025: Focus on VERAXA Biotech AG’s NASDAQ Listing and Internationalization
Xlife Sciences AG released its Half-Year Report 2025 with focus on VERAXA Biotech AG's NASDAQ listing and internationalization. Operational and financial highlights were shared along with clear priorities for H2 2025 -
-
-
COMMUNIQUÉ DE PRESSE
Xlife Sciences AG’s Portfolio Company, VERAXA Biotech AG, Takes Key Step Toward NASDAQ Listing with Filing of Form F-4
Xlife Sciences AG's portfolio company VERAXA Biotech AG takes a key step towards NASDAQ listing with the filing of Form F-4, signaling continued momentum and billion-dollar valuation in the public market journey
